Cancer Immunotherapy
Immune checkpoint inhibitors, CAR-T and TIL cell therapies including solid tumors, T-cell engagers and bispecifics, and antibody-drug conjugates.
Most influential
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative ReviewReview15,256 citationsdoi:10.1159/000455014
- Hepatocellular carcinomaReview7,050 citationsdoi:10.1038/s41572-020-00240-3
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,069 citationsdoi:10.1038/s41588-018-0312-8
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with h…
Abstract excerpt by Zachary Rockow Chalmers et al., CC-BY, https://doi.org/10.1186/s13073-017-0424-2; truncated.
Article3,517 citationsdoi:10.1186/s13073-017-0424-2 - The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, and only subsets of cancer patients can benefit from them. Immune infiltrates in t…
Abstract excerpt by Yuanyuan Zhang et al., CC-BY, https://doi.org/10.1038/s41423-020-0488-6; truncated.
Review2,817 citationsdoi:10.1038/s41423-020-0488-6 - Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseReview3,073 citationsdoi:10.1038/nrclinonc.2016.66
- Antibody drug conjugate: the "biological missile" for targeted cancer therapy
Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the res…
Abstract excerpt by Fu Z et al., CC-BY, https://doi.org/10.1038/s41392-022-00947-7; truncated.
Review1,271 citationsdoi:10.1038/s41392-022-00947-7 - Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeu…
Abstract excerpt by on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group et al., CC-BY, https://doi.org/10.1186/s40425-017-0300-z; truncated.
Article1,992 citationsdoi:10.1186/s40425-017-0300-z - Immune checkpoint inhibitors: recent progress and potential biomarkers
Cancer growth and progression are associated with immune suppression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. Monoclonal antibodies that target immune checkpoints provided an immense breakthrough in cancer therapeutics. Among the immune checkpoint inhibitors, PD-1/PD-L1 and CTLA-…
Abstract excerpt by Darvin P et al., CC-BY, https://doi.org/10.1038/s12276-018-0191-1; truncated.
Review1,602 citationsdoi:10.1038/s12276-018-0191-1 - Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerArticle2,485 citationsdoi:10.1038/nature23003
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapyReview2,285 citationsdoi:10.1038/s41568-019-0116-x
- Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and ResistanceReview2,188 citationsdoi:10.1146/annurev-pathol-042020-0427…
- Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors respond poorly or even not to ICIs, partly caused by the absence of tumor-infiltrating lymphocytes (TILs), significantly limits the application of ICIs. Converting these immune "cold"…
Abstract excerpt by Weitong Gao et al., CC-BY, https://doi.org/10.1038/s41392-022-01046-3; truncated.
Review1,052 citationsdoi:10.1038/s41392-022-01046-3 - Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality. Identification of molecular mechanisms by which cancerous cells evade T cell-mediated cytotoxic damage has led to the modern era of immunotherapy in cancer…
Abstract excerpt by Raju Kumar Vaddepally et al., CC-BY, https://doi.org/10.3390/cancers12030738; truncated.
Review1,198 citationsdoi:10.3390/cancers12030738 - Macrophages as tools and targets in cancer therapyReview1,806 citationsdoi:10.1038/s41573-022-00520-5
Newest work
- The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid TumorsClinical trialNCT07897799
- Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironmentArticledoi:10.1186/s40164-026-00843-8
- Neuronal intermediate filament neurologic autoimmunity in a patient with Merkel cell carcinoma receiving pembrolizumabArticledoi:10.1007/s10072-026-09500-8
- Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trialArticledoi:10.1038/s41467-026-78897-9
- Dysregulation of the Hippo pathway enhances PD-L2 transcription to promote immune evasion in head and neck squamous cell carcinomaArticledoi:10.1038/s42003-026-11092-0
- Cell-Based Assay Development and Standardization for Antibody-Drug ConjugatesArticledoi:10.3390/biotech15040096
- Immune Checkpoint Inhibitor-Associated Pneumonitis in Patients Treated for Metastatic Renal Cell CarcinomaArticledoi:10.3390/curroncol33100616
- From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer OutcomesReviewdoi:10.3390/medsci14060669
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerClinical trialNCT07865910
- Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort StudyArticledoi:10.3390/curroncol33100603
Clinical trials
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsClinical trialNCT05055908
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerClinical trialNCT07865910
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaClinical trialNCT03914625
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerClinical trialNCT06112379
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyClinical trialNCT03959085
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Clinical trialNCT06712316
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Clinical trialNCT03643276
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryClinical trialNCT01274338